Journal of Clinical PracticeJournal of Clinical PracticeКлиническая практика2220-30952618-8627Eco-Vector1896410.17816/clinpract18964ReviewsНаучные обзорыReview ArticleHereditary breast cancer: present status of problemНаследственная форма рака молочной железы: современное состояние проблемыGatuevaF. S.ГатуеваФатима Сослановна
Russian Federation

врач-онколог 3-го хирургического отделения

ledoffcomp@ro.ru9589-9057LyubchenkoL. N.ЛюбченкоЛюдмила Николаевна
Russian Federation

д.м.н., заведующая лабораторией клинической онкогенетики

clingen@mail.ru7066-0295MalyginS. E.МалыгинСергей Евгеньевич
Russian Federation

MD, PhD, assistant professor

к.м.н., доцент кафедры онкологии и лучевой терапии

drmalygin@mail.ruOncological clinical dispensaryРеспубликанский онкологический диспансерN. N. Blokhin National Medical Research Centre of Oncology, Health Ministry of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина»Pirogov Russian National Research Medical UniversityРоссийский национальный исследовательский медицинский университет имени Н.И. Пирогова16042020120520201111031112612201905032020Copyright ©; 2020, Gatueva F.S., Lyubchenko L.N., Malygin S.E.Copyright ©; 2020, Гатуева Ф.С., Любченко Л.Н., Малыгин С.Е.2020Gatueva F.S., Lyubchenko L.N., Malygin S.E.Гатуева Ф.С., Любченко Л.Н., Малыгин С.Е.https://creativecommons.org/licenses/by-nc-nd/4.0https://clinpractice.ru/clinpractice/article/view/18964

The incidence of breast cancer is increasing in most countries every year. The purpose of this literature review is to provide up-to-date information about the causes, mechanisms of development, various methods of prevention, early diagnosis and treatment of hereditary breast cancer. The effectiveness of bilateral preventive mastectomy is discussed.

Показатели заболеваемости раком молочной железы растут в большинстве стран год от года. Цель настоящего обзора литературы — представить современные сведения о причинах, механизмах развития, различных методах профилактики, ранней диагностики и лечения наследственной формы рака молочной железы. Рассматривается эффективность двусторонней профилактической мастэктомии.

hereditary breast cancerprophylactic mastectomyнаследственный рак молочной железыпрофилактическая мастэктомия.Злокачественные новообразования в России в 2016 году (заболеваемость и смертность) / Под ред. Каприна А.Д., Старинского В.В., Петровой Г.В. — М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИРЦ» Минздрава России, 2018. — 250 с. [Zlokachestvennye novoobrazovaniya v Rossii v 2016 godu (zabolevaemost’ i smertnost’). Ed by Kaprin A.D., Starinskii V.V., Petrova G.V. Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMIRTs» Minzdrava Rossii; 2018. 250 p. (In Russ).]Kuusisto KM, Bebel A, Vihinen M, et al. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50 and CDH1 mutations in high-risk finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res. 2011;13(1):R20. doi: 10.1186/bcr2832.Peng L, Xu T, Long T, Zuo H. Association between BRCA status and P53 status in breast cancer: a meta-analysis. Med Sci Monit. 2016;22:1939–1945. doi: 10.12659/msm.896260.Janavičius R. Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J. 2010;1(3):397–412. doi: 10.1007/s13167-010-0037-y.Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–1130. doi: 10.1086/375033.Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98(23):1694–1706. doi: 10.1093/jnci/djj465.Litton JK, Ready K, Chen H, et al. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer. 2012;118(2):321–325. doi: 10.1002/cncr.26284.Bayraktar S, Amendola L, Gutierrez-Barrera AM, et al. Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less. Breast. 2014;23(6):770–774. doi: 10.1016/j.breast.2014.08.010.Kim JY, Moon HG, Kang YJ, et al. The effect of reproductive factors on breast cancer presentation in women who are BRCA mutation carrier. J Breast Cancer. 2017;20(3):279–285. doi: 10.4048/jbc.2017.20.3.279.Cullinane CA, Lubinski J, Neuhausen SL, et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer. 2005;117(6):988–991. doi: 10.1002/ijc.21273.Alsaker MD, Opdahl S, Romundstad PR, Vatten LJ. Association of time since last birth, age at first birth and parity with breast cancer survival among parous women: a register-based study from Norway. Int J Cancer. 2013;132(1):174–181. doi: 10.1002/ijc.27593.Andrieu N, Goldgar DE, Easton DF, et al.; IBCCS Collaborators Group. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst. 2006;98(8):535–544. doi: 10.1093/jnci/djj132.Milne RL, Osorio A, Ramóny Cajal T, et al. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2010;119(1):221–232. doi: 10.1007/s10549-009-0394-1.Kotsopoulos J, Lubinski J, Salmena L. Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2012;14(2):R42. doi: 10.1186/bcr3138.Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and breast cancer risk in the International BRCA1/2 Carrier Cohort Study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating. J Clin Oncol. 2007;25(25):3831–3836. doi: 10.1200/JCO.2007.11.1179.Gronwald J, Byrski T, Huzarski T, et al. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat. 2006;95(2):105–109. doi: 10.1007/s10549-005-9051-5.Lee E, Ma H, McKean-Cowdin R, et al. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3170–3178. doi: 10.1158/1055-9965.EPI-08-0396.Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju091. doi: 10.1093/jnci/dju091.Fischer C, Kuchenbäcker K, Engel C, et al. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium German Consortium for Hereditary Breast and Ovarian Cancer. J Med Genet. 2013;50(6):360–367. doi: 10.1136/jmedgenet-2012-101415.Rosner BA, Colditz GA, Hankinson SE, et al. Validation of Rosner-Colditz breast cancer incidence model using an independent data set, the California Teachers Study. Breast Cancer Res Treat. 2013;142(1):187–202. doi: 10.1007/s10549-013-2719-3.Evans DG, Ingham S, Dawe S, et al. Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme. Fam Cancer. 2014;13(2):189–196. doi: 10.1007/s10689-013-9694-z.Zeichner SB, Stanislaw C, Meisel JL. Prevention and screening in hereditary breast and ovarian cancer. Oncology (Williston Park). 2016;30(10):896–904.Dontu G, El-Ashry D, Wicha MS. Breast cancer/stem progenitor cells and estrogen receptor. Trends Endocrinol Metab. 2004;15(5):193–197. doi: 10.1016/j.tem.2004.05.011.Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–1948. doi: 10.1056/NEJMra1001389.Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25(43):5846–5853. doi: 10.1038/sj.onc.1209876.Daly MB, Pilarski R, Axilbund JE, et al. Genetic/familial high-risk assessment: breast and ovarian, version 2.2015. J Natl Compr Canc Netw. 2016;14(2):153–162. doi: 10.6004/jnccn.2016.0018.Honrado E., Benítez J, Palacios J. Histopathology of BRCA1- and BRCA2-associated breast cancer. Crit Rev Oncol Hematol. 2006;59(1):27–39. doi: 10.1016/j.critrevonc.2006.01.006.Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055–1062. doi: 10.1200/JCO.2004.04.188.Jansen-van der Weide MC, Greuter MJ, Jansen L, et al. Exposure to low-dose radiation and the risk of breast cancer among women with a familial or genetic predisposition: a meta-analysis. Eur Radiol. 2010;20(11):2547–2556. doi: 10.1007/s00330-010-1839-y.Pijpe A, Andrieu N, Easton DF, et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ. 2012;345:e5660. doi: 10.1136/bmj.e5660.Heisey R, Carroll JC. Identification and management of
women with a family history of breast cancer: practical guide for clinicians. Can Fam Physician. 2016;62(10):799–803.Freitas V, Crystal P, Kulkarni SR, et al. The value of breast MRI in high-risk patients with newly diagnosed breast cancer to exclude invasive disease in the contralateral prophylactic mastectomy: is there a role to choose wisely patients for sentinel node biopsy? Cancer Med. 2016;5(6):1031–1036. doi: 10.1002/cam4.663.Passaperuma K, Warner E, Causer PA, et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutation. Br J Cancer. 2012;107(1):24–30. doi: 10.1038/bjc.2012.204.Kurian AW, Sigal BM, Plevritis SK. Plevritis plevritis survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol. 2010;28(2):222–231. doi: 10.1200/JCO.2009.22.7991.Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006;118(9):2281–2284. doi: 10.1002/ijc.21536.Vogel VG. Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women. Breast Cancer (Dove Med Press). 2011;3:127–137. doi: 10.2147/BCTT.S11288.Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014;144(3):443–455. doi: 10.1007/s10549-014-2890-1.Garcia-Etienne CA, Barile M, Gentilini OD, et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol. 2009;16(12):3380–3387. doi: 10.1245/s10434-009-0638-7.Goodwin PJ, Phillips KA, West DW, et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol. 2012;30(1):19–26. doi: 10.1200/JCO.2010.33.0068.Manning AT, Sacchini VS. Conservative mastectomies for breast cancer and risk-reducing surgery: the Memorial Sloan Kettering Cancer Center experience. Gland Surg. 2016;5(1):55–62. doi: 10.3978/j.issn.2227-684X.2015.10.02.Murthy V, Chamberlain RS. Defining a place for nipple sparcing mastectomy in modern breast care: an evidence based review. Breast J. 2013;19(6):571–581. doi: 10.1111/j.1524-4741.2011.01220.x.Peled AW, Wang F, Foster RD, et al. Expanding the Indications for total skin-sparing mastectomy: is it safe for patients with locally advanced disease? Ann Surg Oncol. 2016;23(1):87–91. doi: 10.1245/s10434-015-4734-6.Phillips KA, Milne RL, Rookus MA, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutations. J Clin Oncol. 2013;31(25):3091–3099. doi: 10.1200/JCO.2012.47.8313.Metcalfe KA, Lubinski J, Ghadirian P, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008;26(7):1093–1097. doi: 10.1200/JCO.2007.12.6078.McLaughlin CC, Lillquist PP, Edge SB Surveillance of prophylactic mastectomy: trends in use from 1995 through 2005. Cancer. 2009 Dec 1; 115(23):5404-12.King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol. 2011;29(16):2158–2164. doi: 10.1200/JCO.2010.29.4041.Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159–164. doi: 10.1056/NEJM200107193450301.Fu Y, Zhuang Z, Dewing M, et al. Predictors for contralateral prophylactic mastectomy in breast cancer patients. Int J Clin Exp Pathol. 2015;8(4):3748–3764.Yao K, Liederbach E, Tang R, et al. Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature. Ann Surg Oncol. 2015;22(2):370–376. doi: 10.1245/s10434-014-3883-3.Van Verschuer VM, Maijers MC, van Deurzen CH, Koppert LB. Oncological safety of prophylactic breast surgery: skin-sparing and nipple-sparing versus total mastectomy. Gland Surg. 2015;4(6):467–475. doi: 10.3978/j.issn.2227-684X.2015.02.01.Griepsma M, de Roy van Zuidewijn DB, Grond AJ, et al. Residual breast tissue after mastectomy: how often and where is it located? Ann Surg Oncol. 2014;21(4):1260–1266. doi: 10.1245/s10434-013-3383-x.Benson JR, Dumitru D, Malata CM. Oncologic safety of conservative mastectomy in the therapeutic setting. Gland Surg. 2016;5(1):37–46. doi: 10.3978/j.issn.2227-684X.2015.05.13.Портной С.М., Любченко С.Н., Блохин В.А., и др. Профилактика BRCA-ассоциированных рака молочной железы и рака яичников. Обзор литературы и собственные данные // Онкогинекология. — 2012. — №1. — С. 68–72. [Portnoy SM, Lubchenko LN, Blochin SN, et al. Prophylactic of BRCA1, 2-associated breast and ovarian cancers. Onkoginekologiia. 2012;(1):68–72. (In Russ).]Pinell-White XA, Kolegraff K, Carlson GW. Predictors of contralateral prophylactic mastectomy and the impact on breast reconstruction. Ann Plast Surg. 2014;72(6):S153–157. doi: 10.1097/SAP.0000000000000099.Albornoz CR, Bach PB, Mehrara BJ, et al. A paradigm shift in U.S. Breast reconstruction: increasing implant rates. Plast Reconstr Surg. 2013;131(1):15–23. doi: 10.1097/PRS.0b013e3182729cde.Geiger AM, West CN, Nekhlyudov L, et al. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol. 2006;24(9):1350–1356. doi: 10.1200/JCO.2005.01.9901.Hwang ES, Locklear TD, Rushing CN, et al. Patient-reported outcomes after choice for contralateral prophylactic mastectomy. Clin Oncol. 2016;34(13):1518–1527. doi: 10.1200/JCO.2015.61.5427.Koslow S, Pharmer LA, Scott AM, et al. Long-term patient-reported satisfaction after contralateral prophylactic mastectomy and implant reconstruction. Ann Surg Oncol. 2013;20(11):3422–3429. doi: 10.1245/s10434-013-3026-2.Tondu T, Thiessen F, Tjalma WA. Prophylactic bilateral nipple-sparing mastectomy and a staged breast reconstruction technique: preliminary results. Breast Cancer (Auckl). 2016;10:185–189. doi: 10.4137/BCBCR.S40033.